Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) released its quarterly earnings data on Thursday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.06, Briefing.com reports. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same period in the prior year, the firm posted ($1.26) EPS. The business’s quarterly revenue was down 50.0% compared to the same quarter last year.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $22.71 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. The business has a 50 day simple moving average of $24.18 and a 200-day simple moving average of $23.11. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.67. The stock has a market capitalization of $1.08 billion, a PE ratio of -6.90 and a beta of 0.89.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares in the company, valued at approximately $8,478,032.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 4,584 shares of company stock worth $102,040 in the last three months. Insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCYC. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday. B. Riley lowered shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $33.00 to $28.00 in a research note on Wednesday, August 7th. Oppenheimer restated an “outperform” rating and issued a $48.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.56.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.